Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 12
Submit an article Journal homepage
102
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response

Nadia Peraginea Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
,
Maria Stefania De Proprisa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
,
Stefania Intoppaa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
,
Maria Laura Milania Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
,
Francesca Romana Mauroa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyORCID Iconhttps://orcid.org/0000-0003-2425-9474View further author information
ORCID Icon,
Antonio Cuneob Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, ItalyView further author information
,
Gian Matteo Rigolinb Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, ItalyView further author information
,
Ilaria Del Giudicea Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-6864-9533View further author information
ORCID Icon,
Robin Foàa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyCorrespondence[email protected]
View further author information
&
Anna Guarinic Department of Molecular Medicine, Sapienza University, Rome, ItalyView further author information
 show all
Pages 2982-2986 | Received 10 Mar 2022, Accepted 16 Jul 2022, Published online: 01 Aug 2022

References

  • Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111(2):865–873.
  • Shanafelt TD, Geyer SM, Bone ND, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008;140(5):537–546.
  • Härzschel A, Zucchetto A, Gattei V, et al. VLA-4 expression and activation in B cell malignancies: functional and clinical aspects. Int J Mol Sci. 2020;21(6):2206.
  • Arana E, Harwood NE, Batista FD. Regulation of integrin activation through the B-cell receptor. J Cell Sci. 2008;121(Pt 14):2279–2286.
  • Dal Bo M, Tissino E, Benedetti D, et al. Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. Semin Hematol. 2014;51(3):168–176.
  • de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590–2594.
  • Tissino E, Benedetti D, Herman SEM, et al. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018;215(2):681–697.
  • Arana E, Vehlow A, Harwood NE, et al. Activation of the small GTPase Rac2 via the B cell receptor regulates B cell adhesion and immunological-synapse formation. Immunity. 2008;28(1):88–99.
  • Strati P, Parikh SA, Chaffee KG, et al. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2017;178(1):99–105.
  • Peragine N, De Propris MS, Intoppa S, et al. Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. Haematologica. 2020;106(5):1500–1503.
  • Wang V, Hanson CA, Tschumper R, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021;138(26):2810–2827.
  • Pepper AGS, Zucchetto A, Norris K, et al. Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia. 2022;36(1):271–274.
  • Dal Bo M, Bulian P, Bomben R, et al. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia. 2016;30(10):2011–2018.
  • Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403–1412.
  • Tissino E, Pozzo F, Benedetti D, et al. CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood. 2020;135(15):1244–1254.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.